All In Biotech

Drug Trial Radar · NCT07920185

A Study of Oral SOM001 as a Safe and Effective Treatment for Adults With Chronic Insomnia

A Phase 2a, Multi-center, Randomized, Double-blind, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Tolerability, and Efficacy of Oral SOM001 in Adults With Chronic Insomnia

Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

45

Planned (sponsor's estimate)

Start

Feb 1, 2027

Primary completion

Oct 1, 2027

Study completion Feb 1, 2028

Sponsor

Lead sponsor
Somnum Pharma Inc.Industry
Sponsor type
Industry
First posted
Nov 5, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn if SOM001 is safe and well tolerated in adults with insomnia. It will also evaluate if it helps to improve sleep. The main questions this trial aims to answer are: 1. Is SOM001 associated with any side-effects 2. Do people tolerate SOM001 well 3. Is SOM001 helpful to improve sleep Researchers will compare SOM001 to a placebo (a look-alike substance that contains no drug) as well as to 2 other well-established medications that are often used to treat sleep. Participants will: 1. Take one of the drugs, or placebo for 3 nights each week, for 3 weeks. The drugs will be pre-assigned and change each week. 2. Be asked questions about their sleep and overall health, including mental health 3. Complete tests to evaluate their memory and alertness on the computer 4. Use monitors at night to evaluate their sleep quality and activity. This will be a virtual study and participants will connect with the study team via video and phone calls for training and check-ups during the study.

Conditions

  • Chronic Insomnia

Interventions

  • Low Dose Drug ADrug

    Low Dose Drug A

  • Low Dose Drug BDrug

    Low Dose Drug B

  • High Dose Drug ADrug

    High Dose Drug A

  • High Dose Drug BDrug

    High Dose Drug B

  • SOM001-ADrug

    SOM001-A

  • SOM001-BDrug

    SOM001-B

  • SOM001-CDrug

    SOM001-C

  • SOM001-DDrug

    SOM001-D

  • PlaceboDrug

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with treatment-related adverse events at 3 weeks after SOM001 intervention as compared to placeboTime frame: 3 weeks
  2. Incidence, severity, and relationship of adverse events (AEs) after SOM001 intervention as compared to placeboTime frame: 3 weeks
  3. Incidence of serious adverse events (SAEs) after SOM001 intervention as compared to placeboTime frame: 3 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • 4 East 70th Street, 9a

    New York, New York

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.